Draftkings stock hits 52-week low at 18.55 USD
Source: Investing.com

DraftKings fell to a 52-week low of $18.55, down 47% over the past year, 44% from its $36.98 high, and 12% in the past week. The selloff comes despite 15% month-to-date sports-betting handle growth and analyst Buy/Outperform ratings with $35-$36 price targets. However, higher-than-expected investment in its Predictions product is pressuring forecasts, with StoneX cutting its 2026 EBITDA estimate by $100 million to $575 million and projecting more than $400 million of related investment.
Analysis
DKNG’s issue is not demand but monetization quality: incremental NFL handle can be low-value if it is purchased through promotions, tighter pricing, or prediction-market cross-subsidies. The relevant near-term KPI is gross gaming revenue and contribution profit per incremental handle, not handle growth alone. A material step-up in product investment risks moving the equity from a scalable-platform valuation toward a perpetual customer-acquisition valuation, particularly if FanDuel (FLUT) responds rather than cedes pricing or product share.
Over the next 1-3 months, weekly NFL data can support a technical rebound from an oversold position, but the catalyst must be evidence that promotional intensity is contained and full-year EBITDA expectations remain intact. A lower EBITDA outlook driven by prediction-market spending would be more damaging than equivalent conventional marketing spend because the regulatory end-state, take rate, and state-by-state economics remain unproven. The 6-18 month upside case is that prediction markets expand DKNG’s addressable market and reduce dependence on state wagering legalization; the downside is regulatory restriction or category commoditization, leaving a large spend base with little durable revenue.
Consensus may be too focused on the headline discount to prior trading levels and published price targets. If investment is accelerating while consensus still assumes a clean profitability inflection, estimate risk remains asymmetric: an EBITDA revision can compress both earnings and the multiple simultaneously. Conversely, the selloff is likely overdone only if management can demonstrate that prediction-market losses are capped, customer overlap is incremental rather than cannibalistic, and sportsbook hold/GGR conversion remains stable through the NFL season.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.28
Ticker Sentiment
Key Decisions for Investors
- Maintain DKNG as a watch-list long rather than add aggressively at the low: initiate only after a weekly/monthly read shows GGR or net revenue growth keeping pace with handle while promotional expense remains controlled. Initial risk/reward is favorable only with a stop on a sustained break below $18 or a reduction in full-year EBITDA guidance; target a retracement toward $24-26 over 1-3 months.
- Express competitive-risk caution through a relative trade: long FLUT / short DKNG in equal volatility for the next earnings cycle. FLUT has greater diversification and less single-product execution sensitivity, while DKNG is more exposed to a prediction-market investment overrun; close if DKNG discloses capped spend and stable contribution margins or if the spread widens materially before earnings.
- Do not underwrite analyst profitability forecasts without three confirmatory datapoints: prediction-market spend guidance, net gaming revenue-to-handle conversion, and customer-acquisition/promotional expense trends. Set an alert for any further EBITDA estimate cut of more than 10%; that would likely invalidate a near-term mean-reversion long.
- For existing DKNG holders seeking defined downside, use a 1-3 month collar around the next earnings update rather than buying naked calls. Volatility can remain elevated while the market resolves whether incremental volume is economically accretive, and a technical oversold signal alone is not a sufficient catalyst.
More News
- Stifel reiterates Glaukos stock rating on strong Epioxa survey
- Stifel reiterates Federal Realty stock Hold rating after acquisition
- Stifel reiterates Hold on ResMed stock amid market share concerns
- Analyst sets Tesla (TSLA) stock price target for 12 months
- Stifel cuts Foghorn Therapeutics stock price target on pipeline shift
- Speed of French Bond Rout Is a Concern, StoneX Financial Says
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Software for Buy-Side Teams: Build the Research Stack
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit